<DOC>
	<DOCNO>NCT02395705</DOCNO>
	<brief_summary>The effect neo-adjuvant chemotherapy survival patient thoracic esophageal squamous cell carcinoma remain controversial part neo-adjuvant therapy esophageal carcinoma . One objectives evaluate whether neo-adjuvant therapy cisplatin paclitaxel follow right thoracic approach esophagectomy total 2-field lymph node dissection improve overall survival thoracic esophageal cancer patient .</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy Versus Surgery Alone Esophageal Squamous Cell Carcinoma</brief_title>
	<detailed_description>The effect Neo-adjuvant chemotherapy survival patient thoracic esophageal squamous cell carcinoma remain controversial part Neo-adjuvant therapy esophageal carcinoma . Therefore , optimal management resectable esophageal squamous cell carcinoma differs widely among different area base local randomize controlled trial . The neo-adjuvant chemotherapy might good strategy sufficient local control achieve surgical treatment . This study define detail surgery procedure region lymphadenectomy adopt cisplatin paclitaxel neoadjuvant chemotherapy regimen . We try evaluate efficacy safety neo-adjuvant strategy .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Histologic diagnosis squamous cell thoracic esophageal carcinoma Stage IIA IIIB , ( 7th Union International Cancer Control , UICCTNM ) . 2 . Patients must receive prior anticancer therapy esophageal carcinoma . 3 . Age range 18 75 year . 4 . Without operative contraindication . 5 . Absolute white blood cell count ≥4.0×109/L , neutrophil ≥1.5×109/L , platelet ≥100.0×109/L , hemoglobin ≥90g/L , normal function liver kidney , total bilirubin（TBIL）≤1.5N , aspartate aminotransferase ( AST ) ≤2.5N , alanine aminotransferase ( ALT ) ≤2.5N , prothrombin time ( PT ) ≤1.5N , activate partial thromboplastin time ( APTT ) normal range , endogenous creatinine clearance rate ( CRE ) ≤1.5N . 6 . Patients must diagnose cancer must receive prior anticancer therapy except prostatic cancer 5 year diseasefree survival ( DFS ) . 7. expect R0 resection . 8 . ECOG 0～2 . 9 . Signed informed consent document file . 10.No metastatic lymph node cervical color doppler sonography . 1 . Multiple primary cancer . 2 . The subject understand sign inform consent form ( ICF ) . 3 . Patients concomitant hemorrhagic disease . 4 . Any un expect reason patient ca n't get operation . 5 . Inability use gastric conduit esophagectomy prior surgery . 6 . Pregnant breast feeding . 7 . Patients diagnose suspected allergic cisplatin Paclitaxel .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>